Literature DB >> 28434014

Prospective open-label evaluation of long-term low-dose doxycycline for difficult-to-treat chronic rhinosinusitis with nasal polyps.

A C Pinto Bezerra Soter1, T F Bezerra1, R Pezato1, T R Teles Abdo1, R M Pilan1, F R Pinna1, P Gevaert2, T van Zele2, C Bachert2, R L Voegels1.   

Abstract

BACKGROUND: This study aimed to assess clinical outcomes of long-term low-dose oral doxycycline therapy in difficult-to-treat chronic rhinosinusitis with polyps (CRSwNP).
METHODS: This was a prospective, open-label study of 60 patients with difficult-to-treat CRSwNP who had undergone endoscopic sinus surgery. Patients were divided into two groups: 28 received nasal steroids, saline irrigation, and doxycycline (200 mg on the first day, followed by 100 mg once daily) for 12 weeks, while 30 received only nasal steroids and saline irrigation. The main outcome measure was an adequate effect size of doxycycline treatment on clinically meaningful significant improvement of SNOT-20. Other outcome measures were the SNOT-20, NOSE, and Lund-Kennedy scores. The following parameters were also analyzed: asthma, rhinitis, non-steroidal-exacerbated respiratory disease (NERD), and baseline serum IgG, IgA, IgE, IgM, ANCA, and eosinophil count.
RESULTS: There was an adequate effect size of doxycycline treatment on clinically meaningful significant improvement of SNOT-20. Patients who received doxycycline also had significantly better outcomes regarding SNOT-20, NOSE, and Lund-Kennedy scores. There was a negative association among a clinically significant improvement of SNOT-20 and presence of asthma, NERD, and elevated serum IgE levels before treatment.
CONCLUSION: These findings suggest that doxycycline may have a beneficial role for CRSwNP patients, especially for patients without asthma, NERD or high levels of serum IgE before treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28434014     DOI: 10.4193/Rhino15.291

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  6 in total

1.  [Commentary on the guideline for rhinosinusitis - what is important, what is new?]

Authors:  R Weber
Journal:  HNO       Date:  2018-01       Impact factor: 1.284

Review 2.  Biomarkers in Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Alan D Workman; Michael A Kohanski; Noam A Cohen
Journal:  Immunol Allergy Clin North Am       Date:  2018-09-21       Impact factor: 3.479

3.  Medical Management Strategies in Acute and Chronic Rhinosinusitis.

Authors:  Seong H Cho; Dennis Ledford; Richard F Lockey
Journal:  J Allergy Clin Immunol Pract       Date:  2020-03-03

Review 4.  Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches.

Authors:  Atsushi Kato; Anju T Peters; Whitney W Stevens; Robert P Schleimer; Bruce K Tan; Robert C Kern
Journal:  Allergy       Date:  2021-09-15       Impact factor: 14.710

Review 5.  Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts.

Authors:  Stephan Vlaminck; Frederic Acke; Glenis K Scadding; Bart N Lambrecht; Philippe Gevaert
Journal:  Front Allergy       Date:  2021-10-27

Review 6.  Systemic and topical antibiotics for chronic rhinosinusitis.

Authors:  Karen Head; Lee Yee Chong; Patorn Piromchai; Claire Hopkins; Carl Philpott; Anne G M Schilder; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2016-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.